Trial Profile
Optimal administration of fosaprepitant in patients with colon cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2013
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions
- 25 Sep 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 09 Mar 2013 New trial record